These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 30798422)

  • 1. SNAIL is induced by tamoxifen and leads to growth inhibition in invasive lobular breast carcinoma.
    Bossart EA; Tasdemir N; Sikora MJ; Bahreini A; Levine KM; Chen J; Basudan A; Jacobsen BM; Burns TF; Oesterreich S
    Breast Cancer Res Treat; 2019 Jun; 175(2):327-337. PubMed ID: 30798422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer.
    Alves CL; Elias D; Lyng MB; Bak M; Ditzel HJ
    Breast Cancer Res; 2018 Jun; 20(1):60. PubMed ID: 29921289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines.
    Sikora MJ; Jacobsen BM; Levine K; Chen J; Davidson NE; Lee AV; Alexander CM; Oesterreich S
    Breast Cancer Res; 2016 Sep; 18(1):92. PubMed ID: 27650553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response.
    Sikora MJ; Cooper KL; Bahreini A; Luthra S; Wang G; Chandran UR; Davidson NE; Dabbs DJ; Welm AL; Oesterreich S
    Cancer Res; 2014 Mar; 74(5):1463-74. PubMed ID: 24425047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mediator of DNA Damage Checkpoint 1 (MDC1) Is a Novel Estrogen Receptor Coregulator in Invasive Lobular Carcinoma of the Breast.
    Sottnik JL; Bordeaux EK; Mehrotra S; Ferrara SE; Goodspeed AE; Costello JC; Sikora MJ
    Mol Cancer Res; 2021 Aug; 19(8):1270-1282. PubMed ID: 33947745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Snail-induced epithelial-to-mesenchymal transition of MCF-7 breast cancer cells: systems analysis of molecular changes and their effect on radiation and drug sensitivity.
    Mezencev R; Matyunina LV; Jabbari N; McDonald JF
    BMC Cancer; 2016 Mar; 16():236. PubMed ID: 26988558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential Regulation and Targeting of Estrogen Receptor α Turnover in Invasive Lobular Breast Carcinoma.
    Sreekumar S; Levine KM; Sikora MJ; Chen J; Tasdemir N; Carter D; Dabbs DJ; Meier C; Basudan A; Boone D; McAuliffe PF; Jankowitz RC; Lee AV; Atkinson JM; Oesterreich S
    Endocrinology; 2020 Sep; 161(9):. PubMed ID: 32609836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer.
    Nardone A; Qiu X; Spisak S; Nagy Z; Feiglin A; Feit A; Cohen Feit G; Xie Y; Font-Tello A; Guarducci C; Hermida-Prado F; Syamala S; Lim K; Munoz Gomez M; Pun M; Cornwell M; Liu W; Ors A; Mohammed H; Cejas P; Brock JB; Freedman ML; Winer EP; Fu X; Schiff R; Long HW; Metzger Filho O; Jeselsohn R
    Cancer Res; 2022 Oct; 82(20):3673-3686. PubMed ID: 35950920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Key regulators of lipid metabolism drive endocrine resistance in invasive lobular breast cancer.
    Du T; Sikora MJ; Levine KM; Tasdemir N; Riggins RB; Wendell SG; Van Houten B; Oesterreich S
    Breast Cancer Res; 2018 Sep; 20(1):106. PubMed ID: 30180878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer.
    Walsh L; Haley KE; Moran B; Mooney B; Tarrant F; Madden SF; Di Grande A; Fan Y; Das S; Rueda OM; Dowling CM; Varešlija D; Chin SF; Linn S; Young LS; Jirström K; Crown JP; Bernards R; Caldas C; Gallagher WM; O'Connor DP; Ní Chonghaile T
    Clin Cancer Res; 2019 Dec; 25(23):7139-7150. PubMed ID: 31409615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium Channel Na
    Gradek F; Lopez-Charcas O; Chadet S; Poisson L; Ouldamer L; Goupille C; Jourdan ML; Chevalier S; Moussata D; Besson P; Roger S
    Sci Rep; 2019 Dec; 9(1):18652. PubMed ID: 31819138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteopontin up-regulates critical epithelial-mesenchymal transition transcription factors to induce an aggressive breast cancer phenotype.
    Li NY; Weber CE; Mi Z; Wai PY; Cuevas BD; Kuo PC
    J Am Coll Surg; 2013 Jul; 217(1):17-26; discussion 26. PubMed ID: 23619316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ERRgamma mediates tamoxifen resistance in novel models of invasive lobular breast cancer.
    Riggins RB; Lan JP; Zhu Y; Klimach U; Zwart A; Cavalli LR; Haddad BR; Chen L; Gong T; Xuan J; Ethier SP; Clarke R
    Cancer Res; 2008 Nov; 68(21):8908-17. PubMed ID: 18974135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequent amplifications of ESR1, ERBB2 and MDM4 in primary invasive lobular breast carcinoma.
    Cao L; Basudan A; Sikora MJ; Bahreini A; Tasdemir N; Levine KM; Jankowitz RC; McAuliffe PF; Dabbs D; Haupt S; Haupt Y; Lucas PC; Lee AV; Oesterreich S; Atkinson JM
    Cancer Lett; 2019 Oct; 461():21-30. PubMed ID: 31229512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The transcription factors Slug (SNAI2) and Snail (SNAI1) regulate phospholipase D (PLD) promoter in opposite ways towards cancer cell invasion.
    Ganesan R; Mallets E; Gomez-Cambronero J
    Mol Oncol; 2016 May; 10(5):663-76. PubMed ID: 26781944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated molecular analysis of Tamoxifen-resistant invasive lobular breast cancer cells identifies MAPK and GRM/mGluR signaling as therapeutic vulnerabilities.
    Stires H; Heckler MM; Fu X; Li Z; Grasso CS; Quist MJ; Lewis JA; Klimach U; Zwart A; Mahajan A; Győrffy B; Cavalli LR; Riggins RB
    Mol Cell Endocrinol; 2018 Aug; 471():105-117. PubMed ID: 28935545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterodimer formation by Oct4 and Smad3 differentially regulates epithelial-to-mesenchymal transition-associated factors in breast cancer progression.
    Mandal G; Biswas S; Roy Chowdhury S; Chatterjee A; Purohit S; Khamaru P; Chakraborty S; Mandal PK; Gupta A; de la Mare JA; Edkins AL; Bhattacharyya A
    Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt A):2053-2066. PubMed ID: 29526821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteomic Analysis of Epithelial to Mesenchymal Transition (EMT) Reveals Cross-talk between SNAIL and HDAC1 Proteins in Breast Cancer Cells.
    Palma Cde S; Grassi ML; Thomé CH; Ferreira GA; Albuquerque D; Pinto MT; Ferreira Melo FU; Kashima S; Covas DT; Pitteri SJ; Faça VM
    Mol Cell Proteomics; 2016 Mar; 15(3):906-17. PubMed ID: 26764010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-497 inhibits epithelial mesenchymal transition in breast carcinoma by targeting Slug.
    Wu Z; Li X; Cai X; Huang C; Zheng M
    Tumour Biol; 2016 Jun; 37(6):7939-50. PubMed ID: 26700673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling.
    Scherbakov AM; Sorokin DV; Tatarskiy VV; Prokhorov NS; Semina SE; Berstein LM; Krasil'nikov MA
    IUBMB Life; 2016 Apr; 68(4):281-92. PubMed ID: 26892736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.